Cristina Marzano

Dr. Cristina Marzano

Department of Pharmaceutical and Pharmacological Sciences, University of Padova, via F. Marzolo 5, 35131 Padova, Italy
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2009 in Anti-Cancer Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Cristina MarzanoCristina Marzano
Cristina Marzano
Maura PelleiMaura Pellei
Maura Pellei
FTFrancesco Tisato
Francesco Tisato
Carlo SantiniCarlo Santini
Carlo Santini
Metal-based antitumor drugs play a relevant role in antiblastic chemotherapy. Cisplatin is regarded as one of the most effective drugs, even if severe toxicities and drug resistance phenomena limit its clinical use. Therefore, in recent years there has been a rapid expansion in research and development of novel metal-based anticancer drugs to improve clinical effectiveness, to reduce general toxicity and to broaden the spectrum of activity. The variety of metal ion functions in biology has stimulated the development of new metallodrugs other than Pt drugs with the aim to obtain compounds acting via alternative mechanisms of action. Among non-Pt compounds, copper complexes are potentially attractive as anticancer agents. Actually, since many years a lot of researches have actively investigated copper compounds based on the assumption proposal that endogenous metals may be less toxic. It has been established that the properties of copper-coordinated compounds are largely determined by the nature of ligands and donor atoms bound to the metal ion. In this review, the most remarkable achievements in the design and development of copper(I, II) complexes as antitumor agents are discussed. Special emphasis has been focused on the identification of structure-activity relationships for the different classes of copper(I,II) complexes. This work was motivated by the observation that no comprehensive surveys of copper complexes as anticancer agents were available in the literature. Moreover, up to now, despite the enormous efforts in synthesizing different classes of copper complexes, very few data concerning the molecular basis of the mechanisms underlying their antitumor activity are available. This overview, collecting the most significant strategies adopted in the last ten years to design promising anticancer copper( I,II) compounds, would be a help to the researchers working in this field.

9 March 2011 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
Valentina GandinValentina Gandin
Valentina Gandin
Maura PelleiMaura Pellei
Maura Pellei
FTFrancesco Tisato
Francesco Tisato
MPMarina Porchia
Marina Porchia
Carlo SantiniCarlo Santini
Carlo Santini
Cristina MarzanoCristina Marzano
Cristina Marzano
Platinum anticancer drugs have been used for three decades despite their serious side effects and the emerging of resistance phenomena. Recently, a phosphine copper(I) complex, [Cu(thp)4][PF6] (CP), gained special attention because of its strong antiproliferative effects. CP killed human colon cancer cells more efficiently than cisplatin and oxaliplatin and it overcame platinum drug resistance. CP preferentially reduced cancer cell viability whereas non‐tumour cells were poorly affected. Colon cancer cells died via a programmed cell death whose transduction pathways were characterized by the absence of hallmarks of apoptosis. The inhibition of 26S proteasome activities induced by CP caused intracellular accumulation of polyubiquitinated proteins and the functional suppression of the ubiquitin–proteasome pathway thus triggering endoplasmic reticulum stress. These data, providing a mechanistic characterization of CP‐induced cancer cell death, shed light on the signaling pathways involved in paraptosis thus offering a new tool to overcome apoptosis‐resistance in colon cancer cells.

1 February 2008 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Cristina MarzanoCristina Marzano
Cristina Marzano
Valentina GandinValentina Gandin
Valentina Gandin
Maura PelleiMaura Pellei
Maura Pellei
DCDavide Colavito
Davide Colavito
GPGrazia Papini
Grazia Papini
Carlo SantiniCarlo Santini
Carlo Santini

15 May 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Valentina GandinValentina Gandin
Valentina Gandin
FTFrancesco Tisato
Francesco Tisato
ADAlessandro Dolmella
Alessandro Dolmella
Maura PelleiMaura Pellei
Maura Pellei
Carlo SantiniCarlo Santini
Carlo Santini
MPMarina Porchia
Marina Porchia

18 November 2006 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Cristina MarzanoCristina Marzano
Cristina Marzano
Maura PelleiMaura Pellei
Maura Pellei
DCDavide Colavito
Davide Colavito
SASimone Alidori
Simone Alidori
GLGiancarlo Gioia Lobbia
Giancarlo Gioia Lobbia
Carlo SantiniCarlo Santini
Carlo Santini

1 May 2017 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MJMelanie Jopp
Melanie Jopp
JBJonathan Becker
Jonathan Becker
SBSabine Becker
Sabine Becker
AMAndreas Miska
Andreas Miska
Valentina GandinValentina Gandin
Valentina Gandin
SSSiegfried Schindler
Siegfried Schindler